gastric%20cancer
GASTRIC CANCER
Gastric cancer is the cancer originating in the esophagus, esophagogastric junction and stomach.
Most of gastric cancers are adenocarcinomas, subdivided according to histological appearances into diffuse (undifferentiated) and intestinal (well differentiated) types.
It is the 4th most common cancer and the 2nd most common cause of cancer-related deaths worldwide.
Most common sites of gastric cancer are the proximal lesser curvature, cardia and esophagogastric junction.

Follow Up

  • A regular follow-up may allow investigation & treatment of symptoms, psychological support & early detection of recurrence, though there is no evidence that it improves survival outcomes
  • Response to systemic treatments should normally be assessed with interval computed tomography (CT) imaging of chest, abdomen & pelvis
  • In the advanced disease setting, identification of patients for second-line chemotherapy & clinical trials requires regular follow-up to detect symptoms of disease progression before significant clinical deterioration
  • The type of pathological response & histologic tumor regression after neoadjuvant therapy has been shown to be a predictor of survival
  • Follow-up should include a complete history & physical examination every 3-6 months for 1-2 years, every 6-12 months for 3-5 years & annually thereafter
  • Patients who have undergone surgical resection should be monitored & treated as indicated for vitamin B12 & iron deficiency
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 03 Oct 2017

A new technology involving the use of monocyte-derived hepatocyte-like (MH) cells has demonstrated high sensitivity and specificity in the diagnosis of idiosyncratic drug-induced liver injury (DILI), data presented at the Asian Pacific Digestive Week (APDW) 2017 held in Hong Kong have shown.